Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Monthly revenue–Not shared yet
Rank–Unranked
Last 30 days–Growth in MRR
Revenue per founder–– founders
About Valink Therapeutics
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Discover more startups
Browse the board →MRR
$251K
Last 30 days
-2%
Founder
Jacob Jacquet
MRR
$250K
Last 30 days
0%
Founder
Eugene Zolotarenko
MRR
$250K
Last 30 days
0%
Founder
Valon Asani